ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutini
March 07, 2018Bioverativ Inc. today announced that the first patient has been dosed in the Phase 3 clinical program of its investigational therapy BIVV009 for cold agglutinin disease (CAgD) -
Bioverativ completes acquisition of True North Therapeutics
July 03, 2017Strengthens leadership in rare blood disorders with first-in-class candidate to treat cold agglutinin disease, a chronic autoimmune hemolytic anemia with no approved therapies.
Pharma Sources Insight January 2025
